TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

The TREAD trial is an ongoing randomized controlled trial at UC San Diego testing whether time-restricted eating (TRE) — specifically limiting food intake to a 10-hour daytime window so that nightly fasting extends to 14 hours — can slow Alzheimer's disease (AD) progression in people already showing symptoms. The core idea is that the brain clears toxic proteins like amyloid-beta most efficiently during sleep and prolonged fasting, so eating patterns that protect and extend that overnight clearance window might reduce AD pathology. Participants with Mild Cognitive Impairment (MCI) or early-to-moderate AD are being randomized to either the 14-hour nightly fast or a control condition of less than 12 hours of nightly fasting, with follow-up at 3 and 6 months. The trial will measure changes in AD biomarkers, cognitive performance, and sleep quality, while also tracking whether this population can realistically stick to the regimen. If successful, TRE would represent a non-pharmacological, low-cost intervention that patients could self-administer at home. The study is currently recruiting with an estimated completion date in May 2026. Results are not yet available, so all findings described here reflect the trial's design and scientific rationale, not outcomes.

• No results available yet — the trial is actively recruiting as of the registered completion date of 2026-05-26.
• Primary feasibility question: the study will determine whether adults with MCI or early-to-moderate AD can sustain 14 hours of nightly fasting for 3 to 6 months, a critical prerequisite before efficacy can be claimed.
• Primary mechanistic hypothesis: 14-hour nightly fasting is expected to reduce markers of AD pathology and aging (e.g., amyloid, tau, inflammatory markers) and improve both cognitive and sleep outcomes compared to a less-than-12-hour fasting control condition.

TREAD is a randomized controlled trial (RCT) conducted at the University of California, San Diego, enrolling adults diagnosed with MCI or early-to-moderate Alzheimer's disease. Participants are randomized to a time-restricted eating intervention (food intake confined to a ~10-hour daytime window, yielding ≥14 hours of nightly fasting) versus a control condition (<12 hours of nightly fasting). The trial uses a duration-comparison arm to assess whether 3 months versus 6 months of TRE produces differential benefits on AD pathology biomarkers, cognitive assessments, and polysomnography- or actigraphy-based sleep measures. Sample size and specific biomarker assay details are not fully disclosed in the registered abstract; study completion is projected for May 2026.

Because TREAD is an unpublished, actively recruiting trial, no efficacy or safety data are available and all mechanistic claims remain hypothetical pending results. The population (older adults with cognitive impairment) may face unique adherence challenges — caregiver involvement, appetite dysregulation, and medication timing constraints — that could confound the fasting window measurement and limit generalizability. The trial cannot determine whether any observed benefits stem from TRE per se, reduced caloric intake, improved sleep consolidation, or circadian realignment, as these pathways are deeply entangled. A future experiment combining continuous glucose monitoring, CSF or PET-based amyloid/tau quantification, and actigraphy in a larger multi-site cohort would be needed to disentangle mechanisms and confirm scalability.

TREAD sits at the convergence of circadian biology, metabolic intervention, and neurodegeneration, extending the corpus in a clinically actionable direction. It parallels [§132], which also targets sleep architecture as a lever for cognitive outcomes, but uses a dietary-timing intervention rather than slow-wave sleep enhancement in depression, making the two studies complementary probes of sleep-cognition relationships across different disorders. The trial's circadian-alignment rationale connects directly to [§44], whose mechanistic review of the CLOCK-BMAL1 complex provides the molecular scaffolding for why disrupted circadian rhythms accelerate AD pathology — TREAD's dietary timing manipulation is, in effect, a behavioral attempt to re-entrain that same clock machinery. TREAD also parallels [§96], which investigates neurocognitive impacts of sleep-disordered breathing in older adults; both trials treat sleep quality in aging as a modifiable risk factor for cognitive decline, though through orthogonal interventions. Finally, the gut-microbiome and metabolic remodeling that TRE is known to induce provides indirect resonance with [§133], which explores oxidative stress and circadian disruption as convergent pathological pathways — flagged here as a conceptual bridge rather than a direct comparison given limited metadata on that article.

• Enhancing Slow Wave Sleep in Depression
  Both trials intervene on sleep to improve cognition, but in different populations (AD/MCI vs. depression) and via different mechanisms (dietary timing vs. slow-wave sleep enhancement), enabling a cross-disorder comparison of sleep-cognition leverage points.
• The CLOCK-BMAL1 complex in circadian regulation: structure, mechanisms, and therapeutic targeting
  This mechanistic review of the CLOCK-BMAL1 circadian transcription complex provides the molecular framework underlying TREAD's hypothesis that aligning eating windows with circadian rhythms reduces AD pathology.
• Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
  Both studies examine sleep disturbance as a driver of cognitive decline in older adults, but use independent interventions (TRE vs. sleep apnea management), allowing readers to weigh dietary-circadian versus respiratory routes to neuroprotection.
• Sleep, Light, Circadian, Central Oxidative Stress
  Explores oxidative stress and circadian disruption as overlapping pathological mechanisms, offering a biochemical context for interpreting any biomarker changes TREAD may observe in its AD population.
• Population Based Lighting Study on Older Adults
  A population-based lighting intervention in older adults that, like TREAD, uses a non-pharmacological circadian zeitgeber to modify health outcomes, making it a useful comparator for understanding feasibility and effect sizes of behavioral circadian interventions at scale.